{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-125195","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.533211+00:00","generated_at":"2026-05-15T08:46:52.663599+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"confidence":"high","headline":"Plus Therapeutics appoints Ronald A. Andrews to board; Robert Lenk resigns","bullets":["Robert Lenk resigned as director and Nominating Committee member effective March 20, 2026; no policy disagreement cited.","Ronald A. Andrews appointed to fill vacancy, effective immediately; will stand for reelection at 2026 annual meeting.","Andrews is independent under Nasdaq rules; appointed to Nominating and Corporate Governance Committee.","Andrews brings 35+ years in diagnostics; currently Founder/Managing Partner of The Bethesda Group.","No transactions requiring SEC disclosure; standard indemnification agreement expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-125195","json":"https://secwatch.observer/filing/0001193125-26-125195.json","markdown":"https://secwatch.observer/filing/0001193125-26-125195.md","text":"https://secwatch.observer/filing/0001193125-26-125195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/0001193125-26-125195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526125195/pstv-20260320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:46:52.663599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}